Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Eli Lilly will work with San Diego-based startup Kumquat Biosciences on small-molecule oncology drugs in a deal worth up to $2.07 billion. Lilly will pay…
Eli Lilly is teaming up with Kumquat Biosciences, a startup it has been quietly building a relationship with, to discover small-molecule cancer drugs that…
Bayer and Kumquat enter a global exclusive license/collaboration for Kumquat's KRAS G12D inhibitor (IND cleared July 2025); up to $1.3B including upfront,…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Eli Lilly entered an exclusive research collaboration with Kumquat Biosciences to discover and develop small-molecule immuno-oncology drugs. Kumquat received $70M (cash plus equity) upfront and is eligible for over $2B in preclinical, development and commercial milestones plus royalties on sales.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Kumquat Biosciences, Inc. (this deal) | 2021 | $2.1B | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2021 deals · Eli Lilly and Company deals · Oncology deals